Broadly, compared with conventional therapies, treatment with PD-1/PD-L1 inhibitor monotherapy has been associated with greater tumour response rates, and has been found to decrease the risk of death in both PD-L1-positive and PD-L1-negative patients, although efficacy is highly variable between tumour types [5]. This evidence concerns the gene PDCD1 and neoplasm.